Louise Rodino-Klapac - Mar 4, 2025 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
Head of R&D, CSO
Signature
/s/ Cristin Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac
Stock symbol
SRPT
Transactions as of
Mar 4, 2025
Transactions value $
-$172,683
Form type
4
Date filed
3/6/2025, 08:00 PM
Previous filing
Mar 4, 2025
Next filing
Mar 10, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Tax liability -$173K -1.7K -2.54% $101.34 65.3K Mar 4, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021.